公开(公告)号：US11905285B2

公开(公告)日：2024-02-20

申请号：US17519013

申请日：2021-11-04

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Jeremy Travins ,  Thomas Miller ,  Nikolaos Papaioannou

IPC: C07D471/04 ,  C07D417/04 ,  C07D417/14

CPC classification number: C07D471/04 ,  C07D417/04 ,  C07D417/14

Abstract: Provided herein are compounds that inhibit pKal, a serine protease whose activity is responsible for proteolytically cleaving kininogen and generating the potent vasodilator and pro-inflammatory peptide bradykinin, which can lead to painful and debilitating inflammatory attacks (e.g., edema). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating pKal-related diseases and disorders (e.g., edema) with the compounds in a subject, by administering the compounds and/or compositions described herein.

公开(公告)号：US11685912B2

公开(公告)日：2023-06-27

申请号：US16978417

申请日：2019-03-05

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Brian Dwyer ,  Bohong Zhang ,  Jun Hu ,  Muthuraman Meiyappan ,  Thomas Miller ,  Paul McLean ,  Clark Pan

IPC: C12N9/40 ,  B01J20/286 ,  B01J20/289 ,  B01J20/32

CPC classification number: C12N9/2465 ,  B01J20/286 ,  B01J20/289 ,  B01J20/3219 ,  B01J20/3253 ,  B01J20/3255 ,  C12Y302/01022

Abstract: The invention relates to an affinity resin functionalized with small molecule inhibitors of glycoside-cleaving enzymes, e.g., α-galactosidase A (α-Gal A), glucocerebrosidase (GCB), β-galactosidase, and acid alpha-glucosidase (GAA), and a method for purifying glycoside-cleaving enzymes produced in a cell line using the small molecule inhibitor-functionalized affinity resin.

公开(公告)号：US20220056028A1

公开(公告)日：2022-02-24

申请号：US17519013

申请日：2021-11-04

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Jeremy Travins ,  Thomas Miller ,  Nikolaos Papaioannou

IPC: C07D471/04 ,  C07D417/04 ,  C07D417/14

Abstract: Provided herein are compounds that inhibit pKal, a serine protease whose activity is responsible for proteolytically cleaving kininogen and generating the potent vasodilator and pro-inflammatory peptide bradykinin, which can lead to painful and debilitating inflammatory attacks (e.g., edema). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating pKal-related diseases and disorders (e.g., edema) with the compounds in a subject, by administering the compounds and/or compositions described herein.

公开(公告)号：US11168083B2

公开(公告)日：2021-11-09

申请号：US16636518

申请日：2018-08-03

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Jeremy Travins ,  Thomas Miller ,  Nikolaos Papaioannou

IPC: C07D471/04 ,  C07D417/04 ,  C07D417/14

Abstract: Provided herein are compounds that inhibit pKal, a serine protease whose activity is responsible for proteolytically cleaving kininogen and generating the potent vasodilator and pro-inflammatory peptide bradykinin, which can lead to painful and debilitating inflammatory attacks (e.g., edema). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating pKal-related diseases and disorders (e.g., edema) with the compounds in a subject, by administering the compounds and/or compositions described herein.

公开(公告)号：US20240199602A1

公开(公告)日：2024-06-20

申请号：US18390137

申请日：2023-12-20

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Jeremy Travins ,  Thomas Miller ,  Nikolaos Papaioannou

IPC: C07D471/04 ,  C07D417/04 ,  C07D417/14

CPC classification number: C07D471/04 ,  C07D417/04 ,  C07D417/14

Abstract: Provided herein are compounds that inhibit pKal, a serine protease whose activity is responsible for proteolytically cleaving kininogen and generating the potent vasodilator and pro-inflammatory peptide bradykinin, which can lead to painful and debilitating inflammatory attacks (e.g., edema). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating pKal-related diseases and disorders (e.g., edema) with the compounds in a subject, by administering the compounds and/or compositions described herein.

公开(公告)号：US20230365954A1

公开(公告)日：2023-11-16

申请号：US18201392

申请日：2023-05-24

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Brian Dwyer ,  Bohong Zhang ,  Jun Hu ,  Muthuraman Meiyappan ,  Thomas Miller ,  Paul McLean ,  Clark Pan

IPC: C12N9/40 ,  B01J20/286 ,  B01J20/289 ,  B01J20/32

CPC classification number: C12N9/2465 ,  C12Y302/01022 ,  B01J20/286 ,  B01J20/289 ,  B01J20/3219 ,  B01J20/3253 ,  B01J20/3255

Abstract: The invention relates to an affinity resin functionalized with small molecule inhibitors of glycoside-cleaving enzymes, e.g., α-galactosidase A (α-Gal A), glucocerebrosidase (GCB), β-galactosidase, and acid alpha-glucosidase (GAA), and a method for purifying glycoside-cleaving enzymes produced in a cell line using the small molecule inhibitor-functionalized affinity resin.